选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用

Radiosensitization of Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib on Cervical Carcinoma in Vitro

目的探讨表皮生长因子受体酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用。方法以宫颈鳞癌Siha细胞,腺癌HeLa细胞为研究对象,利用MTT法检测吉非替尼对Siha和HeLa细胞的增殖抑制作用;利用集落形成实验检测吉非替尼对Siha、HeLa细胞的放射增敏效应。结果吉非替尼能够抑制Siha、HeLa细胞的增殖,其IC20值分别是0.15μmol/L、0.32μmol/L,而且抑制作用呈剂量依赖性;吉非替尼作用于Siha、HeLa细胞72h后,放射增敏比SER分别为1.693、1.228。结论吉非替尼对宫颈癌Siha、HeLa细胞具有明显的放射增敏作用。

Objective To study the influence of gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, on the radiosensitivity of human cervical carcinoma cells in vitro. Methods The effect of gefitinib on cervical carcinoma cells （Siha, HeLa） was determined by MTT assay. Cells were assayed for clonogenic survival to determine the radiosensitization effect induced by gefitinih. Restilts The proliferation of cervical carcinoma cell lines （Siha, HeLa） was inhibited by gefitinib, and the effect was dose-dependent. The value of IC2, for the effect of gefitinib on cervical carcinoma cell lines （Stha, HeLa） was 0. 15 μmol/L and 0. 32 μmol/L respectively. When exposed to gefitinib for 72 h, the SER of Siha and HeLa cell was 1. 693 and 1. 228 respectively. Conclusion The selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib can induce radiosensitization of cervical carcinoma cells.